Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity management
Novo Nordisk NVO, +1.48% NOVO.B, +1.88% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity manageme...
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more tre...
Novo Nordisk faces number of overlooked trends including competition for Wegovy, warns investment bank
Novo Nordisk (NYSE:NVO) was the European stock market success of last year, on the back of its anti-obsecity drug Wegovy/Ozempic, but analysts at Jefferies wonder if the valuation may be nearing th...
Novo Nordisk, FDA warn of fake Ozempic
The U.S. Food and Drug Administration has seized thousands of units of fake Ozempic, the agency said Thursday, warning that some counterfeit units of the Novo Nordisk NVO, -0.15% diabetes drug may ...
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
Investing early in an emerging field can sometimes lead to outsize returns. Medicines that extend life spans are going to be big someday.
Why Novo Nordisk Stock Was Up on a Down Day for the Market
An article in "The New York Times" pointed out that Ozempic and Wegovy's active ingredient could have other healing properties. It could help with ovarian disorders, for example, or even help comba...
Why Novo Nordisk Stock Is Moving Higher Today
The overall stock market rise likely helped boost Novo Nordisk's shares. A top Indian online marketplace is also working to halt illegal sales of Novo's weight loss drug Wegovy.
Novo Nordisk owner channels some of Wegovy windfall into respiratory diseases
The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk, has announced an investment of around $265 million to establish a new initiative focused on enhancing vacc...
Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online
One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity a...
Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source
Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a s...
Ozempic and Wegovy lead Novo Nordisk to Yahoo Finance's Company of the Year
Novo Nordisk (NVO) and more specifically its weight-loss drugs Ozempic and Wagovy have been the topic of many conversations across Wall Street. The company's financial performance, impact and buzz ...
Arecor's novel drug formulations could help cut burden on hospitals
Arecor Therapeutics PLC (AIM:AREC)'s chief executive Sarah Howell said the company is at an advanced stage of recruiting patients for phase one trials of rapid ultra-concentrated insulin and should...
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
In studies, Eli Lilly's Mounjaro has demonstrated that it is more effective in helping people lose weight than Ozempic. Street analysts project the weight-loss market to be massive.
Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Novo Nordisk reported strong Q3 results, beating analyst consensus on both top line and earnings. The SELECT CVOT study showed that Wegovy/Ozempic treatment may reduce the risk of death from cardio...
Novo Nordisk: Everything investors need to know
Yahoo Finance selected pharmaceutical firm Novo Nordisk (NVO) as it's 2023 Company of the Year. Developer of obesity medications Wegovy and Ozempic, Novo Nordisk stock has gained over 40% year-to-d...
Related Companies